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Erectile dysfunction (ED) is considered a condition with a broad range of etiologies. Obstructive sleep apnea (OSA) syndrome is one 
of the lesser studied risk factors for ED. We intend to summarize the current evidence on the relationship between OSA and sexual 
impairment, focusing on the results in terms of erectile function of the different therapies offered to OSA patients. A systematic 
review was conducted, selecting articles related to the physiology of OSA and ED, and to the treatments of OSA syndrome and their 
reported outcomes in erectile and sexual function. Higher prevalences of ED in the OSA groups have been published. However, 
whether this effect on the erectile function occurs in the entire range of OSA severities remains unclear. Several hypotheses were 
proposed to explain the physiology of this association. Continuous Positive Airway Pressure as a treatment for OSA patients with ED 
has achieved a significative improvement in the sexual parameters in most of the studies. Phosphodiesterase type 5 inhibitors (iPDE5) 
on demand are useful as a treatment for ED in this subgroup of patients, with high satisfaction rates. The surgical treatment for 
the OSA evidenced benefits over the erectile function, and the effect on the sexual satisfaction of the therapy using Mandibular 
Advancement Devices is still undefined. 
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Erectile dysfunction (ED) is considered a condition with a broad range 
of etiologies. Obstructive sleep apnea (OSA) syndrome, defined as 
a repetitive partial or complete collapse of the upper airway during 
sleep, is one of the lesser studied risk factors for ED. As identification 
and treatment of the causing factors of ED is recommended when 
feasible, knowledge of the outcomes regarding the sexual function 
in OSA patients is important for the urologist. A limited number    
of therapies have been used for OSA treatment, and the outcomes 
over the erectile and the sexual function of these therapies have been 
reported with different methodological approaches and using several 
measuring tools. 
With the hypothesis of a benefit in terms of erectile function in 
the patients with OSA and ED treated for their ventilatory condition, 
we intend to identify and summarize the current published evidence 
in the relationship between OSA and sexual impairment in the male 
population and the results regarding erectile and sexual function of 
the different therapies offered to OSA patients. 
MATERIALS AND METHODS 
A systematic review was conducted and reported following the 
meta-analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines.1 A search in the PubMed database was conducted and 
performed simultaneously by one urologist and one sleep medicine 
specialist, with the same specified strategy. The index terms used 
 
were “sleep apnea,” “obstructive sleep apnea,” “obstructive sleep 
apnea syndrome,” “erectile dysfunction,” “sexual function,” and 
“continuous positive airway pressure.” We  included in our search  
all the studies published before 2015, including the earliest reports 
available in the database, either in urological journals or respiratory 
and sleep medicine ones. Papers published in languages other than 
English were excluded. All types of studies in our initial search were 
included. Reviewing the abstracts, papers related to the physiology 
of OSA and ED, and to the treatments of OSA syndrome and their 
reported outcomes in erectile and sexual function were selected. 
Bibliographies of the retrieved papers were also searched for any 
published papers not showed in the original PubMed search. For 
each selected report, a duplicated data extraction was performed by 
one urologist and one sleep medicine specialist, and the data were 
collected using a template. 
Regarding the outcomes in the sexual and erectile function 
with the different OSA treatments, we described the design of the 
study, the patients and methods, and the results regarding the sexual 
function, and also the ventilatory outcomes when available. The main 
outcome measures of every individual study were identified and 
possible limitations or bias were addressed. When a conflict appeared 
between both reviewers regarding the information in one report, a 
third specialist was asked to clarify this question. We created tables 
to visually expose and compare the heterogeneity of the designs and 
outcomes available for each OSA treatment group. 
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the International Index of Erectile Function (IIEF),10 and the Male 
Sexual Health Questionnaire (MSHQ).11 
After a PubMed search, using a combination of the selected keywords, 
176 articles were identified. From the original collection of abstracts, we 
excluded 110 for different reasons (i.e., focused on female population, 
original in other languages than English, general overviews of only one 
of the conditions or clearly not related with the topic of the search). The 
remaining 66 articles were selected and analyzed (Figure 1). 
In our systematic review, we included the papers related with the 
epidemiology and the physiological hypothesis of the relationship 
between OSA and ED, and those related with the consequences on the 
erectile and sexual function of the treatments for OSA. 
Evidence synthesis 
Importance of ED 
The prevalence of ED varies in different studies depending on age and 
the diagnostic tool used. In males aged 40–70 years old, according to 
Massachusets Male Aging Study (MMAS), ED is severe in 5.1%–15%, 
moderate in 17%–34% and mild in 17% of those studies.2 In worldwide 
studies ED varies between 2%–9% and 20%–30% in the 40–59 years 
old group, 20%–40% in the 60–69 years old group and 50%–75%  
in the 70–80 years old group.3 Currently, ED is considered a mixed 
condition, with both functional and organic causes2 and with a broad 
range of identified risk factors.2–4 One of the main risk factors, with 
direct consequences on respiratory system, is smoking, showing 
direct dose-response association with ED and statistically significant 
differences (adjusted odds ratio = 1.68; 95% CI: 1.03–2.30) in 
exposures ≥20 packs per year.5 Another related factor is the hormonal 
status, such as hypogonadism or androgen deficiency, which has a 
Prevalence of OSA and relationship with ED 
Obstructive Sleep Apnea (OSA) syndrome was reported for first time 
in 1966,12 and it was defined by the American Association of Sleep 
Medicine (AASM) as a repetitive partial or complete collapse of the 
upper airway during sleep that results in disruptions of normal sleep 
architecture and arterial blood desaturations.13 OSA is estimated to 
affect at least 2%–4% of the adult population, with a consistent 2-fold 
risk for males compared to females.14 Furthermore, approximately 
one in four adults is at risk of experience excessive somnolence or 
other OSA-related symptoms.15,16 OSA is associated with a number of 
comorbidities, namely: systemic hypertension, coronary artery disease, 
stroke, congestive heart failure, atrial fibrillation, increased motor 
vehicle accident rate, sleepiness, impaired quality of life, increased 
mortality and erectile dysfunction, and others.17 
A relationship between sleep disturbances and ED was first noticed 
in 1977 by Guilleminault et al.18 and further detailed by Schmidt and 
Wise in 1981.19  Since then, higher prevalences of ED in the OSA 
groups have been published in numerous studies,20–25 depending on 
the diagnostic tool used. The prevalence of ED is as high as 69%,26–28 
with poorer sexual function in OSA patients compared with control 
patients matched for comorbidities and age.23,25,29–31 This growing 
evidence leads to the recommendation in some papers of asking the 
patients about sleep disturbances,25,32–34 or even snoring35 during ED 
assessment. In a survey study, snoring was associated with complaints 
of ED and with an organic ED diagnosis,36 while OSA has been clearly 
named as an independent risk factor for ED,37 with positive correlation 
between both entities.38 In OSA patients, the lower O  saturation was 
prevalence of 5.6% in males between 30 and 79 years old. Of these, 
16% will develop ED.6 When managing ED, it is essential to address a significant predictor (P 
2 
= 0.01) of the presence of ED.34 Despite this 
the cause of the dysfunction, as well as the psycho-social impact on 
the patient and his partner, using a therapeutic approach.7 At the 
same time, we should try to rule out etiologies of ED,8,9  focusing  
on comorbidities and possible modifiable causes.8 Many tools have 
been developed to aid the clinical interview with the patient and 
their partner, to assess the presentation, severity and the response   
to any treatment given.8,9 In most cases, these diagnostic tools are 




Figure 1: Selection of articles. 
data, it remains unclear if this effect on the erectile function occurs in 
the entire range of OSA severities or only in the moderate and severe 
OSA patients.21,23,25,28,30,34 
Physiological hypothesis of the relationship between OSA and ED 
The physiological basis of the association between OSA and ED is still 
a controversial subject since the first papers describing the possible 
hypothesis in 1984.39 This relationship is deeper than the simple 
impairment of sexual function due to depressed mood, daytime 
somnolence, and sleepiness caused by OSA.40 Studies of OSA and ED 
patients treated with antidepressant therapy showed no improvement 
on erectile function despite their depression scale results being 
restored.38 
One theory focuses on the sleep fragmentation related to OSA 
and a lack in Rapid Eye Movement (REM) periods during rest time. 
During REM sleep time, physiological erections appear to help 
maintain erectile function through cavernosal tissue oxygenation.27,30 
Another theory states that the ED is related to changes in the hormonal 
axis caused by sleep pattern changes associated with OSA.41 These 
hormonal changes have been correlated with a lack of libido and sexual 
desire.42 Impairment of the hypotalamus-pituitary-gonadal regulatory 
system leads to a decrease in the release of testosterone,42,43 with low 
testosterone levels being related to the degree of hypoxemia while 
sleeping.43 This suppression of testosterone and sex hormone-binding 
globulin (SHBG) in OSA patients is independent of age and obesity,43 
and is reversed after 3 months of nasal Continuous Positive Airways 
Pressure (CPAP) therapy44 or after surgical treatment.43 Testosterone 
replacement therapy in patients with untreated OSA is contraindicated 
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Norepinephrine release may also have an effect over erectile 
functions in OSA patients, as levels are increased during the 
sympathetic predominant state that follows every apneic episode.47 
A transient hypoxic environment, as in OSA, can also affect changes 
to erectile function in itself, evidenced by a significant (P = 0.05) 
decrease in nocturnal tumescence registers in healthy subjects who 
underwent hypoxia for a short period of time.48 Likewise, in other 
studies, it has been proven that hypoxia leads to neural changes,49 
with evidence of significant (P = 0.007) impairment in pudendal nerve 
transmission and bulbocavernosus reflex, another possible explanation 
for loss of erectile function in OSA patients.50 
A differing hypothesis focuses on a common presentation of ED 
within a proinflammatory state caused by OSA.51,52 This state can lead 
to ED by itself or through other coexisting pathologies.31,53 There is 
growing evidence on the development of ED with a vascular etiology 
in an environment with an excess of free-radicals54 and, in some studies 
conducted on OSA patients, an impairment of endothelial related 
vasodilatation mechanisms was seen.55 Likewise, using animal models, 
low levels of nitric oxide synthase, produced by the endothelium as 
part of the pathway for vasodilatation, are measured in a hypoxic 
environment,56 while other proinflammatory markers are increased, 
leading to low levels of nitric oxide.57,58 In a more practical approach, 
these decreased levels of nitric oxide and its derivatives in plasma 
samples were found to be increased by short- (1 or 2 nights) and 
long-term (1.5 months) CPAP therapy.58,59 
Treatments for OSA and impact of erectile function 
Introduction 
OSA is a chronic disease that requires long-term multidisciplinary 
management. According to the clinical guidelines of the AASM, 
pneumatic splinting of theupper airway by CPAP is thetreatment ofchoice 
for mild, moderate and severe OSA and should be offered as an option 
to all patients. Alternative therapies, such as mandibular advancement 
devices (MADs) and surgical treatments (uvulopalatopharyngoplasty, 
maxillomandibular advancement) may be offered depending on the 
severity of the OSA as well as the patient’s anatomy, risk factors, and 
preferences.60 Success rates, which vary between individuals andtreatment 
options, can be measured in terms of several polysomnographic features, 
symptoms, comorbidities, and quality of life. The vast array of outcome 
measures, together with the variability in individual’s response to 
treatment, makes adequate interstudy comparisons difficult. 
Continuous positive airway pressure (CPAP) (Table 1) 
CPAP is the most widespread and consolidated treatment for OSA 
patients, achieving a significative improvement in respiratory and 
neurological parameters evaluated by polysomnographic studies.61,62 
The first report of improvement of erectile function in OSA patients 
treated with CPAP was published by Karacan and Karatas in 1995.63 
This study was conducted on a cohort of patients diagnosed with OSA 
and sexual dysfunction, performing a polysomnographic test and a 
nocturnal penile tumescence (NPT) register in a basal state and after 
one night using CPAP devices. Previous reports evidenced alterations 
in NPT due to sleep disorders.33 This first study after CPAP treatment 
clearly showed an improvement on the ED parameters in one-third 
of patients.63 Despite the short time of CPAP treatment between tests 
and the absence of clinical assessment of satisfaction following NPT 
changes, this early report offers a first approach to the association 
between OSA and ED. It suggests that the severity of OSA and the 
patient’s age are relevant factors which influence the improvement on 
rigidity with CPAP therapy.63 
Obstructive sleep apnea and erectile dysfunction 
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Since then, several studies have been conducted analyzing the 
changes in erectile function after different lengths of CPAP therapy, 
and in some cases adding other ED treatments as phosphodiesterase 
type 5 inhibitors (iPDE5)22,64–66 or testosterone67 to the positive airway 
pressure therapy. 
Taskin et al.38 in a recently published randomized study, evidenced 
a statistically significant (P < 0.001) improvement in ED, using the 
validated IIEF questionnaire, after at least 1 month of CPAP treatment 
in a cohort of patients diagnosed with severe OSA. They compared 
CPAP therapy with an antidepressant drug (selective serotonin 
reuptake inhibitor) that only showed significantly (P = 0.001) benefit 
in Beck’s depression inventory but not in IIEF-5.38 
Goncalves et al. in a cohort of OSA patients assessed for ED by a 
sexologist interview, found an improvement in the sexual function status 
following 1 month of CPAP therapy in more than 75% of patients.34 
This study also evidenced benefits in the quality of life of patients with 
OSA and ED treated with CPAP, with improvements valued as more 
important in this group than in the group of OSA patients without 
ED treated equally with CPAP. This study demonstrates that erectile 
alteration has a significant (P = 0.02) additional impairment on quality 
of life in OSA patients.34 
In a recently published paper, Cruz et al. assessed the results 
of a cohort of moderate to severe OSA patients treated using nasal 
automatic positive airway pressure (APAP) for at least 6 months.68 
Several parameters, including the presence of ED, were analyzed with 
the Sleep Disorders Questionnaire (SDQ). The prevalence of ED before 
therapy was 25%, and was reduced to 18%, without achieving statistical 
significance.68 One of the most important outcomes of this study is a 
lower ED prevalence when compared with that previous published, 
probably related with the lack of a targeted questionnaire for ED, and 
the absence of any adjustments regarding the severity of ED or OSA, 
leading to poor treatment outcomes.68 
Perimenis et al. studied a group of patients diagnosed with Overlap 
Syndrome (Chronic obstructive pulmonary disease + OSA) and with 
concurrent ED, treated for 6 months with CPAP and bronchodilators, 
finding significant (P < 0.001) improvement in the individual results, 
that were measured with a validated tool (IIEF-5).69 They found that 
this improvement in the erectile function was related positively with 
age and the Apnea-Hypopnea Index (AHI), and negatively with ED 
duration. When patients were simply asked if they were satisfied with 
the effect of the respiratory over their sexual function, only 17% were 
satisfied. However this assessment was not made using a validated 
questionnaire.69 
Margel et al.70 assessed the change in IIEF results on patients 
with OSA treated with at least 1 year of CPAP therapy. They found an 
improvement on sexual function in 20% of patients, correlated with 
adherence and satisfaction with CPAP treatment and with lower levels 
of baseline oxygen saturation. In this study, 18% presented worsening 
in the IIEF results, being less compliant and satisfied with the CPAP 
than the patients with improvement or unchanged erectile function. In 
this study, the low response rate of only 58% of patients who received 
the questionnaire could be a potential limitation for the results. 
The beneficial effect of OSA treatment using CPAP therapy over 
erectile function seems to be maintained in the long-term, according to 
the results published by Budweiser et al.71 In their study, with an average 
follow-up above 3 years, the changes over the baseline erectile function, 
measured within IIEF subscales, showed a significant (P = 0.005) 
decrease in the entire group. However, in mild to moderate ED patients 
with good CPAP compliance, the erectile function improved over 
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Table 1: Outcomes of treatment with CPAP 
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1 month 17 Not reported 76.5% patients 
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and SF‑36 scales 
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ED (25% patients). 
Only 16.6% 
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Budweiser (2013) One cohort 
(interventional) 
CPAP None IIEF‑5 12 months 60 Not reported 20% significant 
improvement 
(more compliant 




CPAP None IIEF‑15 2.5 years 91 Not reported EF decreced 
significantly in 
the entire group. 
Improvement in 
patients with mild 
to moderate ED 
comparing CPAP 















CPAP: continuous positive airway pressure; APAP: automatic positive airway pressure; NPT: nocturnal penile tumescency; IIEF: International Index of Erectile Function; AHI: apnea/hypopnea 
index; BDI: Beck’s depression inventory; SDQ: Sleep Disorders Questionnaire; OSA: obstructive sleep apnea; ED: erectile dysfunction; SF‑36: short form 36 
 
nonusers. In the multivariate regression model, only the age and the 
severity of OSA at diagnosis were predictive for EF impairment, with 
the regular use of CPAP failing to get statistical significance.71 Despite 
these interesting results, the conclusions of Budweiser’s study should 
be carefully assessed, due to the limitations of a mail conducted survey 
with a low response rate (28%) and the lack of adjustment for body 
weight, medications or comorbidities. 
Continuous positive airway pressure and iPDE5 (Table 2) 
Looking for other therapeutic approaches for these patients, Perimenis 
et al. designed a trial based on the need for a combined therapy for 
both entities. They published a new study comparing CPAP treatment 
with CPAP and sildenafil 100 mg on demand for intercourse in a 
group of patients with mild to moderate OSA.22 Analyzing IIEF 
results, the number of intercourses and percentage of successful 
intercourses, they found 61.1% of success in the CPAP + Sildenafil 
arm, significantly (P < 0.001) higher than the 24.7% obtained in the 
CPAP only group. The overall satisfaction with the combined treatment, 
being assessed without a validated questionnaire, was 70% which was 
higher than that achieved with CPAP only.22 
The same group attempted to clarify the importance of each part 
of this therapeutical approach and conducted two randomized trials 
comparing CPAP therapy versus Sildenafil 100 mg on demand in an 
OSA cohort of patients. After 3 months of treatment, they found an 
improvement when comparing with baseline characteristics in both 
groups. However, a significant (P < 0.001) increase in the number of 
sexual intercourses, the percentage of successful intercourse attempts 
and in IIEF results were achieved in the iPDE5 arm,64,65 being the 
benefit in the CPAP group statistically (P = 0.002) but probably not 
clinically significant. Overall satisfaction with the treatment was low 
with both therapies in the two trials, 20% CPAP versus 53.3% Sildenafil 
in the early one65 and 25% CPAP versus 50% Sildenafil in the second 
one,64 but was clearly higher in the group treated with iPDE5. In this 
latter study, a validated questionnaire (EDITS),72 was completed by 
the patients and also by their partners, showing a similar satisfaction 
rate (20% CPAP vs 50% Sildenafil), leading to the need for different 
therapeutic approaches.64 
Using the data of those randomized controlled trials, Li et al. 
performed a meta-analysis, reaching the same conclusions, evidencing 
statistically significant differences toward the sildenafil group in terms 
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Table 2: Outcomes of treatment with CPAP and iPDE5 
Obstructive sleep apnea and erectile dysfunction 




Authors (year) Study design OSA ED ED parameters Length Patients Outcomes Outcomes on ED Bias, weaknesses 
treatment treatment of OSA 
treatment 
(weeks) 
(n) on OSA 
Perimenis (2004)  Randomized 
interventional 
trial (CPAP 












12 30 Not 
reported 
Significant increase in 
number of sexual intercouses 
and in percentage of 
successful intercourse 
attempts (23.9% vs 53.9%) 
IIEF results improve in both 
groups compared with 
baseline (significantly 
higher in iPDE5 group). 
More satisfied with iPDE5 
(53.3% vs 20% not 
statistically significant) 
No treatment 




















12 40 Not 
reported 
Significant increase in 
number of sexual intercourses 
and in percentage of 
successful intercourse 
attempts (26.9% vs 51.4%) 
IIEF results significantly 
improve in both groups 
compared with baseline. 
IIEF significantly higher in 
iPDE5 group compared with 
CPAP. Significantly more 
satisfied with iPDE5 versus 
CPAP (50% vs 25%) 
No treatment 
for OSA in 
iPDE5 arm 
Pastore (2014) Randomized 
interventional 
trial (CPAP 











12 82 Not 
reported 
Significant increase in 
number of sexual intercourses 
and in percentage of 
successful intercourse 
attempts (30.4% vs 58.2%) 
IIEF results significantly 
improve in both groups 
compared with baseline. 
IIEF significantly higher in 
iPDE5 group compared with 
CPAP. Significantly more 
satisfied with iPDE5 versus 
CPAP (68% vs 29%) 
No treatment 






















12 40 Not 
reported 
Significant increase in 
number of intercourses and 
in percentage of successful 
intercourse attempts 
(24.8% vs 61.1%) 
70% overall satisfaction 
Not placebo 
group 
Mean severity of 





CPAP: continuous positive airway pressure; IIEF: International Index of Erectile Function; SEP: sexual encounter profile; AHI: apnea/hypopnea index; EDITS: Erectile Dysfunction Inventory   
of Treatment Satisfaction; iPDE5: phosphodiesterase type 5 inhibitors; OSA: obstructive sleep apnea; ED: erectile dysfunction 
 
of percentage of successful intercourse attempts (P < 0.0001), erectile 
function scores (P < 0.001) and satisfaction of the patient with the 
therapy for ED (P = 0.02).66 
More recently, a new randomized study compared both treatments, 
focusing on patients with severe OSA. Using the same measuring tests, 
Pastore et al. found significant (P < 0.0001) improvement over baseline 
in IIEF-5 in CPAP and sildenafil 100 mg on demand. However when 
comparing the two arms, sildenafil group proved to be more effective 
in terms of successful attempts, IIEF-5 and EDITS results, reaching a 
satisfaction rate of 68%.73 
Despite the good study design and the careful selection of patients, 
with very restrictive exclusion criteria, these studies showed a lack of 
description of the outcomes from the respiratory point of view. Since 
the ED appears to be associated with the OSA syndrome, the treatment 
only of the erectile problem means that the ventilatory dysfunction 
remains untreated, thus risking a worsening of the ED, and developing 
other comorbidities. 
iPDE5 drugs in OSA patients 
Despite the good results  in  Perimenis et  al.  trials, the treatment  
of OSA patients with ED using only iPDE5  is  controversial due 
to the evidence of worsening the ventilatory events in cases 
diagnosed with severe OSA.64 Roizenblatt et al. in a double-blind, 
placebo-controlled, crossover study comparing Sildenafil 50 mg with 
placebo showed an increase in the AHI, and a worsening in oxygen 
saturation in those patients treated with iPDE5, without reporting 
the results in the sexual and erectile function.74 Neves et  al. from  
the same group, evidenced not only a worsening in OSA respiratory 
data but also immediate cardiac effects due to autonomic system 
impairment in Sildenafil-treated patients with severe OSA.75 Since 
these two studies included only 13 severe untreated OSA patients, 
the external validation of the conclusions is compromised. As the 
authors suggested, it is premature to extrapolate these findings to all 
individuals before properly designed randomized, controlled trials on 
the effects of sildenafil and other iPDE5 on pulmonary gas exchange 
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and hemodynamics are performed in patients with different severity 
of sleep-related breathing disorders.74 
Continuous positive airway pressure and surgical treatment (Table 3) 
A recent study from Khafagy and Khafagy confirmed once more the 
benefits of OSA treatment over the erectile function. In this case, the 
benefit arises not only from medical therapy but also from surgical 
treatment in those patients with poor compliance with positive 
pressure treatments.20 They performed a trial, analyzing IIEF-5 
results and nocturnal penile tumescence registered before and after 
3 months of treatment in an heterogeneous cohort of OSA diagnosed 
patients treated with CPAP and an uvulopalatopharyngoplasty (UPP) 
plus adjunctive nasal surgeries. They found a statistically significant 
improvement in respiratory parameters (P < 0.001) and in both erectile 
function tests (P < 0.05).20 Unfortunately, a comparison between the 
two treatment arms was not performed, so the relative value of each 
kind of treatment remains uncertain.20 
Surgical correction of OSA 
Regarding the only surgical management of OSA and the implications 
over ED, it was first suggested by Guilleminault et al. in 1981 with a 
cohort of 49 male OSA patients treated with tracheostomy, a desperate, 
seldom-used surgical intervention that bypasses the upper airway 
granting an unobstructed inspiratory effort and a 100% cure rate. In this 
early report, 44% of patients reported initial difficulty with erections 
and ejaculation, with subsequent disappearance of symptoms after 
surgery in all of the patients except one, after a median follow-up of 
31 months.76 Despite the lack of erectile function assessment validated 
tools, clinical interviews were performed with the patients pre- and 
post-treatment focused on several outcomes including sexual function, 
and the reported results were confirmed with interviews with their 
spouses. 
In 1988, Santamaria et al. conducted a trial in 12 patients 
treated with UPP for OSA.43 They measured serum testosterone in 
OSA patients and snorers, finding statistically significant (P < 0.05) 
lower levels in the first group. Three months after UPP, a complete 
normalization of testosterone levels was reported, and a normal libido 
and sexual function was described in all the patients, with the resolution 




Mandibular advancement devices (Table 3) 
Recently, Shin et al. developed a comparative study between OSA 
surgical treatment with UPP and medical therapies, including 
CPAP and mandibular advancement devices (MADs).77 They 
reported a significant improvement in the erectile function of the 
UPP group (P = 0.039), but not in CPAP or MAD groups. The three 
treatment arms evidenced benefit regarding the quality of life tests 
outcomes, but only reached statistical significance (P = 0.040) in the 
MAD treated group. This paper presents important limitations, such 
a small sample of patients in each group (MAD: 10; CPAP: 16; UPP: 
30), and bias due to the lack of randomization, which led to a different 
profile of severity of OSA and ED in each group with the conclusion 
of the relationship between the severity of ED and a better response 
to the treatment77 being controversial. 
In another randomized controlled  trial Hoekema et  al. in  2007, 
analyzed the sexual function outcomes comparing OSA patients treated 
with CPAP or MAD.29 After 8 weeks of treatment, nostatistically significant 
changes on sexual function results or on testosterone levels from baseline 
were observed in the two groups, but a significant correlation (r = −0.547; 
P < 0.001) was demonstrated between the severity of ED at baseline and 
the improvement after OSA treatment. Despite an adequate study design, 
several limitations arose, as they used a questionnaire uncommon in 
clinical practice (GRISS: Golombok Rust Inventory of Sexual Satisfaction), 
andthere were a small number ofpatients with complete follow-up (MAP: 
14; CPAP: 24) which could affect the conclusions of this trial.29 
DISCUSSION 
The relationship between OSA and ED was described more than   
35 years ago and since then, this topic was approached in different 
investigations. Considering the multifactorial etiology of ED, and 
the variety of the diagnostic tools available, it is understandable of 
the wide range of prevalence of ED described in OSA population. 
Higher prevalences of ED in the OSA groups have been published, 
when compared control patients, matched for age and comorbidities. 
If this effect over the erectile function occurs in the entire range of 
OSA severities or only in severe cases remains controversial. Obesity, 
smoking, and androgen deficiency are conditions directly related with 
ED etiology that may act as confounding factors in OSA patients. 
 
Table 3: Outcomes of treatment with CPAP and surgical correction and MAD 
Authors (year) Study design OSA ED ED Length Patients Outcomes on Outcomes on ED Bias, weaknesses 










































UPP and MAD 
Statistically 
improvement 







Groups of treatment 
not compared 
and no analyzed 
separately 
Not adjusted by 
OSA severity 
Small sample of 
group 
Not randomized 
Not adjusted by OSA 
severity or age 
Hoekema (2007) Randomized 
interventional 















changes in GRISS 
or testosterone 
levels from baseline 
No differences 
between groups 
Small sample of 
patients 
 
CPAP: continuous positive airway pressure; IIEF: International Index of Erectile Function; NPT: nocturnal penile tumescency; UPP: uvulopalatopharyngoplasty; MAD: mandibular advancement 
device; AHI: apnea/hypopnea index; ESS: epworth sleepiness scale; GRISS: Golombok Rust Inventory of Sexual Satisfaction; OSA: obstructive sleep apnea; ED: erectile dysfunction 
 





Regarding the bases linking both conditions, several hypothesis has 
been proposed to explain the physiology of this association. The first 
and more obvious one was related with the mood and the sleepiness 
caused by OSA. There are also clear evidences supporting the theory 
of hormonal changes related with the impaired sleep pattern and the 
hypoxic environment during apneic episodes. Recent studies suggest 
that ED in this context is caused by endothelial dysfunction, as part 
of a systemic proinflammatory state caused by OSA, and leading to 
decreased levels of nitric oxide. 
CPAP is the treatment of choice for OSA patients. The effects 
over erectile and sexual function showed benefits after only one night 
of treatment and maintained in the long-term. These studies, based 
on cohorts of patients treated with CPAP therapy, evidenced an 
improvement on erectile function in around 30% of patients, with a 
broad range between 6% and 76%. As predictors for ED improvement, 
the patient’s age, the severity of the OSA and the adherence to CPAP 
treatment were suggested, but not consistent in all the studies. 
The best level of evidence in the relationship between OSA 
treatment and ED is comparing the CPAP and the iPDE5 (sildenafil), 
with one meta-analysis published in this topic and four well-designed 
randomized clinical trials. Sildenafil 100 mg on demand proved 
important improvement in erectile function tests (around 50%) 
compared with CPAP, also achieving better satisfaction results. In 
these trials CPAP alone also improved the erectile function around 
20%. When both therapies were offered together, the higher overall 
satisfaction was achieved (70%). The combined approach with CPAP 
and Sildenafil ensures an adequate treatment for OSA, as there is some 
evidence regarding worsening in respiratory data and cardiac effects 
in severe OSA patients treated with iPDE5 only. 
The published studies about erectile function outcomes after 
surgical treatment of OSA are very heterogeneous. The first reports 
showed promising outcomes with tracheostomy, a treatment currently 
seldom used. The UPP also showed benefit, but the measure of the 
outcomes in the papers was controversial, and the number of the 
patients included in the studies was small. 
MAD is the less studied OSA treatment regarding the effects over 
the erectile function, but in a well-designed randomized trial, it failed 
to prove benefits.28 
As limitations of our study, we performed a descriptive analysis of 
the published evidence, without any statistical comparison between 
groups of treatments or between individual studies. Heterogeneity 
between selected articles was found, with consequent differences in 
the level of evidence provided. We only selected reports published in 
English, but we will broaden our search including reports published in 
urological and also respiratory and sleep medicine journals in the future. 
CONCLUSIONS 
There is growing evidence of the risk of ED in OSA patients. Despite the 
lack of knowledge of the mechanisms of the sexual problems in these 
patients, there is a proven relationship between the severity of both 
entities. It seems to be reasonable to recommend asking about the sleep 
disorders during the erectile dysfunction clinical interview, due to the 
fact that the treatments of sleep disordered breathing will improve the 
sexual results, in particular, CPAP therapy. The iPDE5 on demand seems 
to be a good treatment for the ED in this cohort of patients, with the best 
outcomes and satisfaction rates when associated with CPAP therapy. 
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